World Journal of Gastroenterology,
Journal Year:
2024,
Volume and Issue:
31(5)
Published: Dec. 30, 2024
Colorectal
cancer
(CRC)
is
the
third
most
commonly
diagnosed
and
second
leading
cause
of
death
worldwide.
The
risk
factors
for
CRC
include
male
gender,
age
over
50,
family
history,
obesity,
tobacco
smoking,
alcohol
consumption,
unhealthy
diet.
screening
methods
vary
considerably
between
countries
depend
on
incidence,
economic
resources
healthcare
structure.
Important
aspects
adherence,
which
can
significantly
across
ethnic
socioeconomic
groups.
Basic
concepts
pre-stratification
patients
by
identifying
then
using
fecal
immunochemical
test
or
guaiac-based
occult
blood
and/or
colonoscopy
radiologic
imaging
techniques.
Technological
capabilities
are
rapidly
evolving
stool
DNA
test,
liquid
biopsy,
virtual
colonography,
use
artificial
intelligence.
A
prevention
strategy
should
be
comprehensive
active
patient
education
along
with
targeted
implementation
screening.
World Journal of Gastroenterology,
Journal Year:
2024,
Volume and Issue:
30(2), P. 115 - 127
Published: Jan. 10, 2024
Small
nucleolar
RNAs
(snoRNAs)
represent
a
class
of
non-coding
that
play
pivotal
roles
in
post-transcriptional
RNA
processing
and
modification,
thereby
contributing
significantly
to
the
maintenance
cellular
functions
related
protein
synthesis.
SnoRNAs
have
been
discovered
possess
ability
influence
cell
fate
alter
disease
progression,
holding
immense
potential
controlling
human
diseases.
It
is
suggested
dysregulation
snoRNAs
cancer
exhibits
differential
expression
across
various
types,
stages,
metastasis,
treatment
response
and/or
prognosis
patients.
On
other
hand,
colorectal
(CRC),
prevalent
malignancy
digestive
system,
characterized
by
high
incidence
mortality
rates,
ranking
as
third
most
common
type.
Recent
research
indicates
snoRNA
associated
with
CRC,
differs
between
normal
cancerous
conditions.
Consequently,
assessing
level
function
holds
promise
for
diagnosis
CRC.
Nevertheless,
current
comprehension
CRC
remains
limited.
This
review
offers
comprehensive
survey
aberrant
regulation
providing
valuable
insights
into
discovery
novel
biomarkers,
therapeutic
targets,
tools
furnishing
critical
cues
advancing
judicious
selection
targets.
Practical Laboratory Medicine,
Journal Year:
2024,
Volume and Issue:
unknown, P. e00446 - e00446
Published: Dec. 1, 2024
Liquid
biopsy
is
an
innovative,
minimally
invasive
diagnostic
tool
revolutionizing
cancer
management
by
enabling
the
detection
and
analysis
of
cancer-related
biomarkers
from
bodily
fluids
such
as
blood,
urine,
or
cerebrospinal
fluid.
Unlike
traditional
tissue
biopsies,
which
require
procedures,
liquid
offers
a
more
accessible
repeatable
method
for
tracking
progression,
detecting
early-stage
cancers,
monitoring
therapeutic
responses.
The
technology
primarily
focuses
on
analyzing
circulating
tumor
cells
(CTCs),
DNA
(ctDNA),
other
cancer-derived
genetic
materials.
These
provide
critical
information
heterogeneity,
mutation
profiles,
potential
drug
resistance.
In
clinical
practice,
has
demonstrated
its
utility
in
identifying
actionable
mutations,
guiding
personalized
treatment
strategies,
assessing
minimal
residual
disease
(MRD).
While
holds
immense
promise,
challenges
related
to
sensitivity,
specificity,
standardization
remain.
Efforts
optimize
pre-analytical
analytical
processes,
along
with
establishment
robust
regulatory
frameworks,
are
crucial
widespread
adoption.
This
abstract
highlights
transformative
diagnosis,
prognosis,
monitoring,
emphasizing
role
advancing
oncology.
Further
research,
trials,
harmonization
will
be
vital
realizing
full
precision
care.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(4), P. 1648 - 1648
Published: Feb. 14, 2025
Colorectal
cancer
(CRC)
is
a
leading
cause
of
cancer-related
deaths
worldwide,
characterized
by
high
incidence
and
poor
survival
rates.
Glycosylation,
fundamental
post-translational
modification,
influences
protein
stability,
signaling,
tumor
progression,
with
aberrations
implicated
in
immune
evasion
metastasis.
This
study
investigates
the
role
glycosylation-related
genes
(Glycosylation-RGs)
CRC
using
machine
learning
bioinformatics.
Data
from
The
Cancer
Genome
Atlas
(TCGA)
Molecular
Signatures
Database
(MSigDB)
were
analyzed
to
identify
67
differentially
expressed
Glycosylation-RGs.
These
used
classify
patients
into
two
subgroups
distinct
outcomes,
highlighting
their
prognostic
value.
Weighted
gene
coexpression
network
analysis
(WGCNA)
revealed
key
modules
associated
traits,
including
pathways
like
glycan
biosynthesis
PI3K-Akt
signaling.
A
machine-learning-based
model
demonstrated
strong
predictive
performance,
stratifying
high-
low-risk
groups
significant
differences.
Additionally,
correlations
between
risk
scores
cell
infiltration,
providing
insights
microenvironment.
Drug
sensitivity
identified
potential
therapeutic
agents,
Trametinib,
SCH772984,
Oxaliplatin,
showing
differential
efficacy
groups.
findings
enhance
our
understanding
glycosylation
CRC,
identifying
it
as
critical
factor
disease
progression
promising
target
for
future
strategies.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(7), P. 3070 - 3070
Published: March 27, 2025
Early
detection
of
colorectal
cancer
(CRC)
significantly
improves
overall
prognosis
and
increases
5-year
survival
rates
up
to
90%.
Current
non-invasive
screening
methods
for
CRC,
such
as
the
Faecal
Immunohistochemical
Test
(FIT),
have
some
drawbacks,
namely,
low
sensitivity
a
high
false-positive
rate.
The
Sialyl-Tn
(STn)
antigen,
frequently
expressed
in
pre-malignant
lesions
adenocarcinomas,
has
been
shown
be
detected
by
novel
monoclonal
antibody
L2A5.
In
this
study,
we
explored
potential
L2A5
CRC
method
an
attempt
overcome
current
limitations.
subjects
were
categorised
into
four
groups
based
on
colonoscopy
findings:
no
lesion
(NL),
low-grade
dysplasia
(LGD),
high-grade
(HGD),
(CRC).
Slot
blot
analysis
using
was
performed
stool
samples
from
95
patients.
Our
findings
showed
differential
STn
expression
between
different
clinical
groups,
evidencing
excellent
discrimination
NL
(AUC,
0.8252;
95%
CI:
0.6983-0.9521;
sensitivity,
70%).
Moreover,
moderate
NL+LGD
HGD+CRC
discerned
0.7766;
0.6792-0.8740;
58%).
These
support
application
tool
detecting
STn,
allowing
identification
advanced
screening.
